Neurological disorders

Addex Convenes Annual General Meeting 2021

Retrieved on: 
Friday, May 14, 2021
Organic compounds, Parkinson's disease, Dipraglurant, Imidazopyridines, Organofluorides, Chemical compounds, Nervous system, Neurological disorders, Dystonia, Dyskinesia, Levodopa-induced dyskinesia, L-DOPA, Organic compounds, Parkinson's disease, Dipraglurant, Imidazopyridines, Organofluorides, Chemical compounds, Nervous system, Neurological disorders, Dystonia, Dyskinesia, Levodopa-induced dyskinesia, L-DOPA

In accordance with the COVID-19 Ordinance 3, the Board of Directors ordered that all shareholders may exercise their rights at the Annual General Meeting (AGM) exclusively through the Independent Voting Rights Representative, Robert P. Briner, attorney-at-law, B & B Avocats.

Key Points: 
  • In accordance with the COVID-19 Ordinance 3, the Board of Directors ordered that all shareholders may exercise their rights at the Annual General Meeting (AGM) exclusively through the Independent Voting Rights Representative, Robert P. Briner, attorney-at-law, B & B Avocats.
  • Addex\xe2\x80\x99s lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson\xe2\x80\x99s disease levodopa induced dyskinesia (PD-LID) in Q2 2021.
  • Addex is also investigating dipraglurant\'s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q2 2021.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.\n'

2020 Spinal Muscular Atrophy Pipeline Insights - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Health, Pharmaceutical, Branches of biology, Neurological disorders, Medical specialties, Spinal muscular atrophy, Pipeline, Drug pipeline, Androgen receptor, Muscle atrophy

b'The "Spinal Muscular Atrophy - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThe "Spinal Muscular Atrophy - Pipeline Insight, 2020," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points: 
  • b'The "Spinal Muscular Atrophy - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThe "Spinal Muscular Atrophy - Pipeline Insight, 2020," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThis segment of the Spinal Muscular Atrophy report encloses its detailed analysis of various drugs in the different stages of clinical development, including phase II, I, preclinical and Discovery.
  • It is currently in phase I stage of development.\nSNA based therapeutics is being developed by Exicure for the treatment of Spinal muscular atrophy.
  • phase III include Kowa and others.\nSpinal Muscular Atrophy pipeline report provides therapeutic assessment of the pipeline drugs by the Route of Administration.\n'

The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Abnormal psychology, Autism, Psychiatric diagnosis, Psychiatry, Pervasive developmental disorders, Learning disabilities, Neurological disorders, Autism spectrum, Conditions comorbid to autism spectrum disorders, Spectrum disorder, Diagnosis of Asperger syndrome

The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.

Key Points: 
  • The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.
  • However, common and rare inherited genetic variations along with non-inherited traits contribute to the development of ASD.
  • According to DSM-5, patients with ASD face difficulties in social interaction, communication, activities, and nonverbal interactions; and show repetitive patterns of behaviors.
  • "Also, the growing awareness of autism spectrum disorder (ASD) has encouraged early detection and diagnosis, therefore, allowing access to services to more children as early as possible.

The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Abnormal psychology, Autism, Psychiatric diagnosis, Psychiatry, Pervasive developmental disorders, Learning disabilities, Neurological disorders, Autism spectrum, Conditions comorbid to autism spectrum disorders, Spectrum disorder, Diagnosis of Asperger syndrome

The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.

Key Points: 
  • The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.
  • However, common and rare inherited genetic variations along with non-inherited traits contribute to the development of ASD.
  • According to DSM-5, patients with ASD face difficulties in social interaction, communication, activities, and nonverbal interactions; and show repetitive patterns of behaviors.
  • "Also, the growing awareness of autism spectrum disorder (ASD) has encouraged early detection and diagnosis, therefore, allowing access to services to more children as early as possible.

Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury

Retrieved on: 
Wednesday, May 12, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical trials, Branches of biology, Neurological disorders, Nervous system, Medical specialties, Preterm birth, Neurology, Brain damage, Neurodevelopmental disorder, Neuroprotection, TT-20, Tellus Therapeutics, Inc., Xontogeny, LLC, TT-20, TELLUS THERAPEUTICS, INC., XONTOGENY, LLC

Neonatal WMI is the most common brain injury leading to neurodevelopmental disability in survivors of preterm birth.

Key Points: 
  • Neonatal WMI is the most common brain injury leading to neurodevelopmental disability in survivors of preterm birth.
  • The mechanism of action is reparative and independent of the cause of WMI, thereby providing an advantage over neuroprotective approaches that target only injury prevention.
  • Current medical response consists solely of supportive care, as no treatments are currently approved to treat newborns with white matter brain injury.
  • Tellus Therapeutics, Inc. undertakes no obligation to update any forward-looking statements for any reason.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005289/en/\n'

2021 Global Friedreich's Ataxia Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Health, Genetics, Neurological disorders, Rare diseases, Nikolaus Friedreich, Ataxia, Trinucleotide repeat disorders, Autosomal dominant disorders, Harding ataxia, Friedreich's ataxia

b'The "Global Friedreich\'s Ataxia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Friedreich\'s Ataxia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Friedreich\'s Ataxia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Friedreich\'s Ataxia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Friedreich\'s Ataxia patients, history of the disease at the population level (Friedreich\'s Ataxia prevalence, Friedreich\'s Ataxia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Friedreich\'s Ataxia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Friedreich\'s Ataxia market sizing, assessing market potential, and developing drug forecast models\nIdentify Friedreich\'s Ataxia patients segments through age groups, gender, and disease sub-types\nEvaluate Friedreich\'s Ataxia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005433/en/\n'

Zogenix to Participate in the BofA Securities 2021 Healthcare Conference

Retrieved on: 
Tuesday, May 11, 2021
Neurological disorders, Health, Clinical medicine, Epilepsy, Dravet syndrome, CDKL5, Lennox–Gastaut syndrome, Syndromes, Fenfluramine, Epilepsy-intellectual disability in females, Epilepsy syndromes

b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • b'Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The company\xe2\x80\x99s first rare disease therapy, FINTEPLA\xc2\xae (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy.
  • The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
  • Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.\n'

Worldwide Neuroprosthetics Industry to 2029 - Spinal Cord Stimulation Spearheads the Global Market

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurological disorders, Pain, Neural engineering, Neuromodulation, Spinal cord, Neuroprosthetics, Upper motor neuron lesion, Functional electrical stimulation

Spinal cord stimulation is the most widely adopted modality for neuroprosthesis along with deep brain stimulation.

Key Points: 
  • Spinal cord stimulation is the most widely adopted modality for neuroprosthesis along with deep brain stimulation.
  • In majority of the spinal cord injury cases, some nerve fibers remain in contact with the brainstem to the spinal cord, which allows application of spinal cord stimulation possible.
  • Over the past two decades, the field of spinal cord stimulation interventions exploiting the development of neuromodulation for spinal cord injuries have phenomenally evolved.\nBased on the application areas, the global neuroprosthetics market is categorized into motor neuron disorders, physiological disorders, and cognitive disorders.
  • Neuroprosthetics are gaining wide usage in treatment of Parkinson\'s disease, essential tremors, spinal cord injuries, following the success of deep brain and spinal cord stimulation.

2021 Report on the Global Spinal Muscular Atrophy Market - Epidemiology and Patient Flow - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Surgery, Health, Physical therapy, Neurological disorders, Branches of biology, Medical specialties, Motor neuron diseases, Neuromuscular Disorders, Gross pathology, Neurogenetic disorders, Muscle atrophy, Atrophy, Draft:Hamano Tsukamoto Syndrome, Spinal muscular atrophies

b'The "Global Spinal Muscular Atrophy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Spinal Muscular Atrophy epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Spinal Muscular Atrophy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Spinal Muscular Atrophy epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Spinal Muscular Atrophy patients, history of the disease at the population level (Spinal Muscular Atrophy prevalence, Spinal Muscular Atrophy incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSpinal Muscular Atrophy patient flow: Spinal Muscular Atrophy prevalence, diagnosed, and drug-treated patients\nDemographics: Spinal Muscular Atrophy patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Spinal Muscular Atrophy market sizing, assessing market potential, and developing drug forecast models\nIdentify Spinal Muscular Atrophy patients segments through age groups, gender, and disease sub-types\nEvaluate Spinal Muscular Atrophy market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005653/en/\n'

Alnylam Announces New Advances in ATTR Amyloidosis Program

Retrieved on: 
Tuesday, May 11, 2021
General Health, Pharmaceutical, Health, Branches of biology, Biology, Biotechnology, Amyloidosis, Alnylam Pharmaceuticals, Therapeutic gene modulation, Neurological disorders, RNA, Protein folding, Familial amyloid polyneuropathy, Transthyretin, RNA interference, HELIOS-A Phase 3 Study, Vutrisiran, hATTR Amyloidosis, IKARIA™ Platform, RNAi, Alnylam Pharmaceuticals, HELIOS-A PHASE 3 STUDY, VUTRISIRAN, HATTR AMYLOIDOSIS, IKARIA™ PLATFORM, RNAI, ALNYLAM PHARMACEUTICALS

In addition, the Company announces today advancement of a new pre-clinical ATTR amyloidosis program aimed at achieving highly potent and reversible TTR reduction of over 90 percent with an annual subcutaneous dosing regimen.\n\xe2\x80\x9cAlnylam has a long-standing commitment to continuous innovation aimed at providing breakthrough treatment options for patients with ATTR amyloidosis.

Key Points: 
  • In addition, the Company announces today advancement of a new pre-clinical ATTR amyloidosis program aimed at achieving highly potent and reversible TTR reduction of over 90 percent with an annual subcutaneous dosing regimen.\n\xe2\x80\x9cAlnylam has a long-standing commitment to continuous innovation aimed at providing breakthrough treatment options for patients with ATTR amyloidosis.
  • Patients will undergo periodic assessments for safety and TTR reduction, and efficacy assessments at months nine and 18 of the RTE.
  • Alnylam expects results from the RTE study in 2022; if positive, data would support a supplemental NDA (sNDA) submission to the FDA.\nThe new ATTR program announced today stems from continued innovation from Alnylam\xe2\x80\x99s RNAi therapeutics platform efforts.
  • Alnylam plans to present data from its IKARIA platform and ALN-TTRsc04 program at a scientific meeting in mid-2021.\n\xe2\x80\x9cOur platform team continues to discover innovations for RNAi therapeutics that we believe can deliver meaningful advances for patients.